SL
SELLAS Life Sciences Group, Inc.
SLS · NASDAQ
$11.38 -2.39% (-$0.28)
1M -20.66%
Market Cap $2.12B
P/E Ratio -
Div. Yield -
ROE 35.91%
Bulios Fair Price
$6.15
45.9% downside
Current Price
$11.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SLS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 15.38x
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 144.46%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 22.33%
ROIC 25.45%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 18.83x
Debt/Equity 0.01x
Debt/Assets N/A
Stability
44 /100
Moderate Profitable years 0
Beta 2.53x
EPS volatility 12.80%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Angelos Stergiou
Employees
13
Headquarters
New York
Upcoming events
11 NOV
Earnings
Upcoming earnings report